Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Post by moneywagonon Oct 19, 2022 12:10pm
96 Views
Post# 35033874

BIOV LUNCH TIME OVER 800K~MILLION PLUS EOD for for shore!!

BIOV LUNCH TIME OVER 800K~MILLION PLUS EOD for for shore!!
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   8.0 0.185 · 0.19 0.5 0.195 +0.04 25.8 822.0 139 169 0.16  0.195  0.16 0.465  0.085 11:40:39 Oct 14 15 min RT 2¢
CSE - C 8.0 0.185 · 0.19 0.5 0.195 +0.04 25.8 369.2 62 91 0.16  0.195  0.16 0.465  0.085 11:40:39   15 min
NEO ATS - U   0.19 +0.035 22.6 348.5 61 34 0.17  0.195  0.17   11:39:38   15 min
Omega - O   0.175 +0.02 12.9 87.0 14 21 0.17  0.19  0.17   10:46:14   15 min
CX2 - H   0.185 +0.03 19.4 12.5 2 9 0.175  0.185  0.175   10:49:54   15 min
CXD - D   0.155     0.2   1        Jul 04   15 min
TriAct - M   0.155     4.6 0 13            15 min

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities